BackgroundCheck.run
Search For

John B Mathison, 414179 3Rd Ave UNIT 405, San Diego, CA 92103

Related to:
Judith A Mathison 73

John Mathison Phones & Addresses

San Diego, CA   

Chula Vista, CA   

Jamaica Plain, MA   

Brookline, MA   

Ventura, CA   

Watertown, MA   

Get Report
Control this profile

Mentions for John B Mathison

Career records & work history

License Records

John B Mathison

Address:
Boston, MA 02120
Licenses:
License #: 9510709 - Expired
Issued Date: Feb 19, 2009
Expiration Date: Oct 14, 2011
Type: Salesperson

John Mathison resumes & CV records

Resumes

John Mathison Photo 33

Event Producer

Location:
San Diego, CA
Industry:
Events Services
Work:
Premier Event Productions
Event Producer
Education:
Berklee College of Music 2001 - 2006
Bachelors, Bachelor of Arts, Music, Business Management
Skills:
Event Production, Stage Management, Set Design, Audio, Video, Rigging, Lighting
John Mathison Photo 34

Scientist At The Scripps Research Institute

Location:
San Diego, CA
Industry:
Research
Work:
The Scripps Research Institute
Scientist at the Scripps Research Institute
Education:
Scripps Research
John Mathison Photo 35

John Mathison

Publications & IP owners

Us Patents

Methods And Compositions For Inhibiting Cd14 Mediated Cell Activation

US Patent:
6444206, Sep 3, 2002
Filed:
Oct 13, 1998
Appl. No.:
09/170769
Inventors:
Didier J. Leturcq - San Diego CA
Ann M. Moriarty - Poway CA
Richard J. Ulevitch - Del Mar CA
Peter S. Tobias - San Diego CA
John C. Mathison - San Diego CA
Assignee:
The Scripps Research Institute - La Jolla CA
International Classification:
A61K 39395
US Classification:
4241411, 4241441, 435343, 5303887
Abstract:
This invention provides hybridoma cell lines producing monoclonal antibodies which inhibit CD14 mediated cell activation. Monoclonal antibodies produced by these cell lines also are provided. The antibodies are useful for the detection of the presence of cell surface and soluble CD14 in a sample. Chimeric and CDR grafted antibodies generated from the above monoclonal antibodies are further provided. Pharmaceutical compositions containing the above biological compositions are provided. These are useful to treat and prevent disorders with CD14 mediated cell activation, such as sepsis.

Methods And Compositions For Ameliorating The Symptoms Of Sepsis

US Patent:
6495332, Dec 17, 2002
Filed:
Oct 2, 2001
Appl. No.:
09/970338
Inventors:
Richard Ulevitch - Del Mar CA
Peter Tobias - Encinitas CA
Samuel D. Wright - New York NY
John C. Mathison - San Diego CA
Assignee:
The Sripps Research Institute - La Jolla CA
The Rockefeller University - New York NY
International Classification:
G01N 3353
US Classification:
435 72, 435 29, 435334
Abstract:
The present invention concerns a method of treating sepsis comprising administering a therapeutically effective amount of anti-CD14 antibody molecules. A therapeutic composition comprising anti-CD14 antibody molecules in a pharmaceutically acceptable excipient is also contemplated.

Hybrid Cells Producing Monoclonal Anti-Cd14 Antibodies

US Patent:
7326569, Feb 5, 2008
Filed:
Sep 3, 2002
Appl. No.:
10/236051
Inventors:
Didier J. Leturcq - San Diego CA, US
Ann M. Moriarty - Poway CA, US
Richard J. Ulevitch - Del Mar CA, US
Peter S. Tobias - San Diego CA, US
John C. Mathison - San Diego CA, US
Assignee:
The Scripps Research Institute - La Jolla CA
International Classification:
C12N 5/06
C07K 21/08
US Classification:
435326, 435346, 5303881
Abstract:
This invention provides hybridoma cell lines producing monoclonal antibodies which inhibit CD14 mediated cell activation. Monoclonal antibodies produced by these cell lines also are provided. The antibodies are useful for the detection of the presence of cell surface and soluble CD14 in a sample. Chimeric and CDR grafted antibodies generated from the above monoclonal antibodies are further provided. Pharmaceutical compositions containing the above biological compositions are provided. These are useful to treat and prevent disorders with CD14 mediated cell activation, such as sepsis.

Methods And Compositions For Ameliorating The Symptoms Of Sepsis

US Patent:
6297049, Oct 2, 2001
Filed:
Apr 3, 2000
Appl. No.:
9/542118
Inventors:
Richard Ulevitch - Del Mar CA
Peter Tobias - Encinitas CA
Samuel D. Wright - New York NY
John C. Mathison - San Diego CA
Assignee:
The Scripps Research Institute - La Jolla CA
International Classification:
G01N 3353
C12N 506
A61K 39395
C07K 1600
US Classification:
435335
Abstract:
The present invention concerns a method of treating sepsis comprising administering a therapeutically effective amount of anti-CD14 antibody molecules. A therapeutic composition comprising anti-CD14 antibody molecules in a pharmaceutically acceptable excipient is also contemplated.

Methods And Compositions For Ameliorating The Symptoms Of Sepsis

US Patent:
5730980, Mar 24, 1998
Filed:
Oct 25, 1994
Appl. No.:
8/328554
Inventors:
Richard Ulevitch - Del Mar CA
Peter Tobias - Encinitas CA
Samuel D. Wright - New York NY
John C. Mathison - San Diego CA
Assignee:
The Scripps Research Institute - La Jolla CA
International Classification:
C07K 1600
C07K 1618
A61K 37395
C12P 2108
US Classification:
4241541
Abstract:
The present invention concerns a method of treating CD14-mediated host inflammatory response to LPS often associated with sepsis comprising administering a therapeutically effective amount of anti-CD14 antibody molecules. A therapeutic composition comprising anti-CD14 antibody molecules in a pharmaceutically acceptable excipient is also contemplated.

Methods And Compositions For Ameliorating The Symptoms Of Sepsis

US Patent:
6045795, Apr 4, 2000
Filed:
Aug 5, 1997
Appl. No.:
8/906400
Inventors:
Richard Ulevitch - Del Mar CA
Peter Tobias - Encinitas CA
Samuel D. Wright - New York NY
John C. Mathison - San Diego CA
Assignee:
The Scripps Research Institute - La Jolla CA
International Classification:
A61K 39395
US Classification:
4241541
Abstract:
The present invention concerns a method of treating sepsis comprising administering a therapeutically effective amount of anti-CD14 antibody molecules. A therapeutic composition comprising anti-CDl4 antibody molecules in a pharmaceutically acceptable excipient is also contemplated.

Methods And Compositions For Inhibiting Cd14 Mediated Cell Activation

US Patent:
5820858, Oct 13, 1998
Filed:
Jan 23, 1995
Appl. No.:
8/373297
Inventors:
Didier J. Leturcq - San Diego CA
Ann M. Moriarty - Poway CA
Richard J. Ulevitch - Del Mar CA
Peter S. Tobias - San Diego CA
John C. Mathison - San Diego CA
Assignee:
The Scripps Research Institute - La Jolla CA
International Classification:
A61K 39395
G01N 33567
C07K 1600
C07H 2104
US Classification:
4241331
Abstract:
This invention provides monoclonal antibodies that bind to the cell surface CD14 receptor and soluble CD14 receptor. The antibodies are useful for the detection of the presence of cell surface and soluble CD14 in a sample. Chimeric and CDR grafted antibodies generated from the above monoclonal antibodies are further provided. Pharmaceutical compositions containing the above biological compositions are provided. These are useful to treat and prevent LPS-associated disorders, such as sepsis.

Isbn (Books And Publications)

Treasures Of The Transformed Life: Satisfying Your Soul'S Thirst For More

Author:
John Ed Mathison
ISBN #:
0687334357

Treasures Of The Transformed Life: Satisfying Your Soul'S Thirst For More

Author:
John Ed Mathison
ISBN #:
0687334454

Treasures Of The Transformed Life: Satisfying Your Soul'S Thirst For More Participants Workbook

Author:
John Ed Mathison
ISBN #:
0687334551

Tried And True: Eleven Principles Of Church Growth From Frazer Memorial United Methodist Church

Author:
John Mathison
ISBN #:
0881771171

Every Member In Ministry

Author:
John Mathison
ISBN #:
0881771929

Possible Relatives

David B Mathison  Deborah Mathison  Aaron M Mathison  Dennis H Mathison  Donna M Mathison  Douglas Mathison  Duane R Mathison  John M Johnson  John Stamps  John R Stan 

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.